Why the study?
Does the detection of ACPA improve the early diagnosis and prognosis of rheumatoid arthritis?
Does the detection of ACPA improve the early diagnosis and prognosis of rheumatoid arthritis?
Answers are grounded in this paper and cite their sources.
ACPA are highly specific and sensitive biomarkers for the early diagnosis and prognosis of rheumatoid arthritis, potentially guiding early aggressive therapy.
Anti-perinuclear factor and anti-keratin antibodies have long been known to be specifically associated with rheumatoid arthritis (RA). They were first demonstrated to target various forms of (pro)filaggrin, a protein of stratified epithelia. Then, they were found to belong to a single family of autoantibodies targeting proteins that bear peptidic epitopes centered by a citrullyl residue: the anti-citrullinated protein autoantibodies (ACPA). The main targets of ACPA in the synovial tissue were demonstrated to be citrullinated forms of the a- and beta-chains of fibrin. A chronic conflict between locally produced ACPA and deposits of citrullinated fibrin is probably responsible for self-maintaining of RA synovial inflammation. Various tests for the detection of ACPA have been developed: recent ELISAs confirm their high diagnostic specificity and improve their diagnostic sensitivity. Since ACPA appear very early in the course of the disease, their detection is of major interest to identify RA among recent arthritides. Moreover, their prognostic value may lead to start early 'aggressive' treatments to prevent irreversible joint damage.
No takes yet. Share an insight, caveat, or question.
Vincent et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: